Results 261 to 270 of about 6,020,192 (375)
Objectives Rapid advances in transcriptomics have driven efforts to identify deregulated pathways in multiple sclerosis (MS) tissues, though many detected differentially expressed genes are likely false positives, with only a small fraction reflecting actual pathological events. Robust, integrative methods are essential for accurately understanding the
Gianmarco Abbadessa+11 more
wiley +1 more source
Therapeutic Advances in Pediatric Multiple Sclerosis. [PDF]
Walsh R, Chitnis T.
europepmc +1 more source
ON THE FINE STRUCTURE OF THE DISTRIBUTION OF MULTIPLE SCLEROSIS
John F. Kurtzke
openalex +1 more source
Multiple sclerosis (MS) and Alzheimer's disease are neurodegenerative diseases with age‐related disability accumulation. In MS, inflammation spans decades, whereas AD is characterized by Aβ plaques and neurofibrillary tangles (NFT). Few studies explore accumulation of amyloids in MS.
J. Pansieri+8 more
wiley +1 more source
Human synenkephalin [1–53] (hSYN), an analogue peptide of shrew saliva neurotoxins, was synthesized and its structural characteristics studied. Synthetic hSYN potently activated the T‐type voltage‐gated Ca channel hCav3.2 but did not paralyze mealworms. These findings offer new insight into neurological disorder treatment and evolutionary mechanisms of
Ryo Fukuoka+5 more
wiley +2 more sources
Hypoxic Neuroinflammation in the Pathogenesis of Multiple Sclerosis. [PDF]
Hollingworth BYA+3 more
europepmc +1 more source
UNC13A Polymorphism Influences Survival in Patients with Frontotemporal Dementia
UNC13A (rs12608932‐CC) is associated with both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), and shortens survival in ALS. We aim to describe the association for UNC13A and survival in FTD. We included 626 patients with FTD from Dutch memory clinics, including a subcohort of 150 patients with TDP‐43 pathology. Survival analyses
Lianne M. Reus+19 more
wiley +1 more source
Biaryl Phosphates and Phosphonates as Selective Inhibitors of the Transcription Factor STAT4
The transcription factor STAT4 is a therapeutic target for autoimmune diseases. Here, para‐biaryl phosphates and phosphonates are presented as the first small‐molecule inhibitors of STAT4. The phosphonate Stafori‐1 selectively stabilizes STAT4 against thermal denaturation in cell lysates, and its cell‐permeable prodrug Pomstafori‐1 selectively inhibits
Nadiya Brovchenko+7 more
wiley +2 more sources